Morningstar
•
Oct 29, 2026
Illumina, Inc.: Illumina Earnings: Market Disappointed That Growth Has Not Accelerated Further
Summary
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina’s high-throughput technology enables whole genome
Upgrade to begin using premium research reports and get so much more.
Exclusive reports, detailed company profiles, and best-in-class trade insights to take your portfolio to the next level
UpgradeRelated Reports
Analyst Report: DexCom, Inc.
Oct 30, 2026
•
DXCM
Market Update: CB, F, FLEX, ISRG, TSCO, VZ
Oct 30, 2026
•
VZ, F, FLEX, TSCO, ISRG, CB
Analyst Report: Intuitive Surgical Inc
Oct 30, 2026
•
ISRG
Analyst Report: Thermo Fisher Scientific Inc
Oct 30, 2026
•
TMO
Market Digest: AMZN, TT, KLAC, LLY, LMT, MSFT, PSA, TMO, MA, AGNC, HLT, STRL
Oct 30, 2026
•
TT, KLAC, MSFT, HLT, LMT, MA, AGNC, TMO, LLY, STRL, AMZN, PSA
Analyst Profile
Julie Utterback
Senior Analyst
Julie Utterback is a senior equity analyst for Morningstar Research Services LLC, a wholly owned subsidiary of Morningstar, Inc. She covers life sciences firms in the healthcare industry.Utterback initially joined Morningstar in 2005 as an equity analyst in the healthcare industry. At that time, she covered medical technology companies, including orthopedic device, medical equipment, and cardiac device firms. In 2010, she joined Morningstar's credit research team, initiating coverage on the entire healthcare industry and generally helping the organization expand and maintain its credit coverage across many industries. She held that senior credit analyst role until rejoining the equity team in April 2019.Prior to joining Morningstar, Utterback was an equity analyst at State Farm Insurance for several years. She holds a bachelor's degree in finance from the University of Illinois Urbana- Champaign. She also holds the Chartered Financial Analyst® designation.
